AI Article Synopsis

  • Chronic recurrent multifocal osteomyelitis is a rare bone inflammation predominantly seen in children, with no standardized treatment protocols established.
  • A study conducted on 12 pediatric patients revealed a common age of 11 years, with frequent occurrence in locations like the ankle and clavicle, and a high rate of recurrences.
  • Treatment usually involves anti-inflammatory medications, with intravenous pamidronate suggested as an alternative for cases resistant to standard therapies, while anti-TNF drugs may be considered for those who do not respond to pamidronate.

Article Abstract

Introduction: Chronic recurrent multifocal osteomyelitis is a rare aseptic bone inflammation that affects pediatric patients. Its management and treatment have not yet been standardized.

Methods: Retrospective, descriptive study of patients under 14 years of age diagnosed with chronic nonbacterial osteomyelitis (CNBO) in a tertiary hospital. We included patients diagnosed over the last 6 years (2010-2015) who met the Jansson criteria. The clinical and radiological characteristics of CNBO were analyzed, as was the outcome after different therapeutic options.

Results: We report 12 patients, with a mean age of 11 years (±1.6 standard deviation [SD]) and female predominance (10:2). The mean number of foci was 3.5 (±2.2 SD). The most common locations were ankle (58%), clavicle (50%), sternum (33%) and hip (25%). The mean disease duration was 10.5 months (±10.3 SD), and the median time to diagnosis was 2.38 months (range 0.17-16). Bone scintigraphy detected asymptomatic foci in 33% and we detected lytic lesions in 50% through magnetic resonance imaging. Biopsy was performed in 60%; 2/12 (16%) were associated with inflammatory disease and 1/12 (8.3%) later developed lymphoma. In all, 58% received antibiotic therapy with little response, 100% anti-inflammatory agents, 50% systemic corticosteroids, 41.6% methotrexate/pamidronate and 16% anti-tumor necrosis factor (TNF) α. The mean duration of treatment was 14.8 months (±12.4 SD) and 66% had recurrences. Currently, 83% are in clinical remission without treatment.

Conclusions: When CNBO is refractory to treatment with anti-inflammatory drugs, intravenous pamidronate can be an alternative. Anti-TNF drugs can be considered in patients who fail with pamidronate, as can agents associated with other autoimmune conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reuma.2017.04.002DOI Listing

Publication Analysis

Top Keywords

recurrent multifocal
8
multifocal osteomyelitis
8
patients
5
osteomyelitis children
4
children experience
4
experience tertiary
4
tertiary care
4
care center
4
center introduction
4
introduction chronic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!